Skip to main content
. 2024 Oct 4;109(10):3157–3166. doi: 10.3324/haematol.2023.284409

Figure 4.

Figure 4.

Cumulative incidence of relapses and non-relapse death. Probabilities were estimated using the Kaplan-Meier method. Patients not achieving remission were counted as event at time zero for the cumulative incidence of relapse (blue line). Patients dying while in remission achieved as a result of inotuzumab ozogamicin (InO) treatment were counted as event in the non-relapse death curve (red line).